Lantheus Holdings

Lantheus Holdings, Inc. engages in the provision of diagnostic imaging and nuclear medicine products. The firm develops products that help healthcare professionals in patient management and outcomes and assists clinicians with the detection of cardiovascular disease. It operates through the U.S. and International geographical segments. The U.S. segment produces and markets products, radiopharmacies, PMFs, integrated delivery networks, hospitals, clinics, and group practices throughout the United States. The International segment offers direct distribution in Canada and Puerto Rico, third-party distribution in Europe, Canada, Australia, Asia-Pacific, and Latin America, and the EXINI business in Sweden. The company was founded in 1956 and is headquartered in North Billerica, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Lantheus reports record revenues in 2022, eyes sustained growth

Lantheus' strong financial performance and market leadership position it well for continued growth.
While facing competition and investment challenges, Lantheus is focused on innovation and market expansion.
The company's strategic acquisitions, pipeline expansion, and guidance for 2023 signal a positive outlook.
Lantheus aims to maintain profitability while investing in key areas for future growth and market leadership.

Lantheus Holdings reports record Q1 results and eyes oncology growth

Lantheus Holdings delivered robust Q1 results driven by key products, with strong revenue and margin performance.
The company's strategic acquisitions and pipeline advancements position them well for future growth in oncology and Alzheimer's diagnostics.
While facing challenges with certain programs and undisclosed cancer types, Lantheus has outlined clear opportunities for market expansion and new treatment avenues.

Lantheus Holdings excels in Q2, eyes European expansion and innovation

Lantheus Holdings delivered robust Q2 2023 results, showcasing strong revenue growth and operational impact, with raised guidance reflecting confidence in sustained performance.
The company's focus on differentiation, market leadership, and strategic partnerships positions it well for growth despite competitive and regulatory challenges.
Opportunities in expanding market reach, diversification through radiotherapeutic candidates, and product innovation present avenues for future growth and market dominance.
Navigating challenges in competition, regulatory changes, and supply chain optimization will be crucial for Lantheus to maintain its market-leading position and drive continued success.

Lantheus Holdings excels in Q3 with strong revenue growth and market leadership

Lantheus Holdings' strong Q3 performance, driven by robust revenue growth and strategic advancements, positions the company well for future success. Despite challenges such as fixed costs and seasonal fluctuations, Lantheus remains focused on leveraging opportunities in the growing radiopharmaceutical market. With a leading market share, innovative pipeline, and solid financial position, Lantheus is poised for continued growth and value creation.

Lantheus Holdings achieves record revenues, eyes growth in radiopharmaceuticals

Lantheus Holdings delivered strong financial performance in 2023 with record revenues and growth.
The company is strategically positioned to capitalize on opportunities in radiopharmaceuticals and oncology.
Challenges include managing potential product transitions and maintaining market leadership.
Overall, Lantheus shows promise for continued growth and innovation in the healthcare sector.

Lantheus Holdings excels in Q1 2024, eyes $1B sales

Lantheus Holdings delivered a strong performance in Q1 2024, driven by robust sales of PYLARIFY and operational excellence, showcasing financial strength and profitability.
The company's focus on innovation, strategic partnerships, and pipeline opportunities positions it well for future growth and market leadership in radioligand therapy.
While facing challenges in a competitive landscape and evolving industry dynamics, Lantheus has opportunities for revenue growth, market expansion, and strategic collaborations to drive long-term success.

Lantheus Holdings excels in Q2 with strong sales and strategic acquisitions

Lantheus Holdings delivered strong financial performance in Q2 2024, driven by PYLARIFY's robust sales and strategic acquisitions strengthening their pipeline.
Despite facing challenges such as regulatory uncertainties and market competition, Lantheus remains well-positioned for growth and market leadership.
With a focus on innovation, market leadership, and strategic acquisitions, Lantheus is poised to capitalize on opportunities in the radiopharmaceutical market and drive sustained growth.

Lantheus Holdings reports robust Q3 performance amidst market opportunities

Lantheus Holdings (LNTH) delivered a strong performance in Q3 2024, driven by key products and revenue growth.
The company faces challenges in navigating market uncertainties and maintaining growth momentum.
Opportunities lie in expanding market presence, capitalizing on reimbursement changes, and advancing Alzheimer's diagnostics.
Overall, Lantheus Holdings shows promise for future growth and innovation in the healthcare sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Lantheus Holdings, Inc. engages in the provision of diagnostic imaging and nuclear medicine products. The firm develops products that help healthcare professionals in patient management and outcomes and assists clinicians with the detection of cardiovascular disease. It operates through the U.S. and International geographical segments. The U.S. segment produces and markets products, radiopharmacies, PMFs, integrated delivery networks, hospitals, clinics, and group practices throughout the United States. The International segment offers direct distribution in Canada and third-party distribution relationships in Europe, Canada, Australia, Asia-Pacific, Central America, and South America. The company was founded in 1956 and is headquartered in Bedford, MA.

Lantheus Holdings, Inc.'s (LNTH) CEO Mary Anne Heino on Q2 2020 Results - Earnings Call Transcript

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc.

Lantheus Holdings, Inc. Reports Second Quarter 2020 Financial Results

Lantheus Holdings to Host Second Quarter 2020 Earnings Conference Call on July 30, 2020 at 8:00 a.m. Eastern Time

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture and commercialization of innovative diagnostic and therapeutic agents and products, today announced that 17 abstracts highlighting PyL™ (18F-DCFPyL) have been selected for presentation at the virtual Society of Nuclear Medicine and Molecular Imaging (SNMMI) 20

Lantheus Holdings to Showcase the Potential of PyL™ Imaging Agent at the Virtual Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2020 Annual Meeting

NORTH BILLERICA, Mass. & NEW YORK--(BUSINESS WIRE)--Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today announced that it has completed its previously announced merger with Progenics Pharmaceuticals, Inc. (“Progenics”) (Nasdaq: PGNX), an oncology company developing innovative medicines and artificial i

Lantheus Completes Merger with Progenics

Lantheus Holdings, Inc. (LNTH) CEO Mary Anne Heino on Q1 2020 Results - Earnings Call Transcript

Shares of Lantheus Holdings (NASDAQ:LNTH) remained unaffected at $14.03 after the company reported Q1 results.

Recap: Lantheus Holdings Q1 Earnings

Lantheus Holding, Inc. (LNTH) CEO Mary Anne Heino on Q4 2019 Results - Earnings Call Transcript

Lantheus Holding Inc. (LNTH) CEO Mary Anne Heino on Q3 2019 Results - Earnings Call Transcript

Progenics Pharmaceuticals

Micro-cap biotech Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) is advancing strongly following an announcement concerning a buyout deal.

Lantheus To Acquire Progenics Pharma In All-Stock Deal

Shares tumble after the company announces a surprise acquisition.

Why Lantheus Holdings Is Dropping Today

President & CEO of Lantheus Holdings Inc (30-Year Financial, Insider Trades) Mary Anne Heino (insider trades) sold 25,538 shares of LNTH on 09/03/2019 at an average price of $21.21 a share.

Lantheus Holdings Inc (LNTH) President & CEO Mary Anne Heino Sold $541,661 of Shares

Lantheus Holding Inc. (LNTH) CEO Mary Anne Heino on Q2 2019 Results - Earnings Call Transcript

Lantheus Holdings (LNTH) delivered earnings and revenue surprises of 0.00% and -3.49%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Lantheus Holdings (LNTH) Q2 Earnings Match Estimates

Lantheus Holdings (LNTH) CEO Mary Anne Heino on Q1 2019 Results - Earnings Call Transcript

Lantheus Holdings (LNTH) delivered earnings and revenue surprises of 12.00% and -0.33%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Lantheus Holdings (LNTH) Q1 Earnings Top Estimates

LNTH vs. CLPBY: Which Stock Is the Better Value Option?

News for Lantheus Holdings Stock (LNTH)